Day: April 8, 2022

The Annual General Meeting of Hofseth BioCare ASA will be held at the company’s premises at Kipervikgata 13, 6003 Ålesund, on 29 April 2022 at 13:00 CET. Please find the notice to the Annual General Meeting attached and relevant documents referred to in the notice are made available on www.hofsethbiocare.com. For further information, please contact: Jon Olav Ødegård, CFO of Hofseth BioCare ASA Phone: +47 93632966 E-mail: joo@hofsethbiocare.no About Hofseth BioCare ASA HBC is a Norwegian consumer and pet health ingredient supplier and an incubator for new drug leads. Research is ongoing to identify the individual elements within its ingredients that modulate inflammation and the immune response with pre-clinical studies in multiple clinics and university research labs in several countries. Lead clinical and pre-clinical candidates...

Stockholm, 8 April 2022 – Anoto Group AB (publ) (“Anoto”) announced in a press release on 6 April 2022 that the loan Anoto received from Swedish investors that was announced in a press release on 10 August 2021 now partially is converted into shares. The conversion referred to is carried out through an offset issue. The Board of Directors of Anoto has, on the basis of an authorization from the Annual General Meeting held on 30 June 2021, resolved on an offset issue of 6,666,666 shares (the “Offset issue”). Through the Offset issue, Anoto receives MSEK 5 through set-off before issue costs. The disapplication of the shareholders´ preferential rights are for Anoto to be able fulfill its obligations according to the loan agreement entered into. The subscription price for the Offset issue is 0.75 SEK per share, which corresponds to the volume-weighted...

MAINZ, Germany, April 8, 2022 — BioNTech SE (Nasdaq: BNTX) today announced that it is one of the companies in Germany to be granted a pandemic preparedness contract by the Federal Republic of Germany. The framework agreement is aimed at pandemic preparedness including manufacturing and supply of mRNA vaccines in emergency situations in Germany. “There is growing evidence that viral pandemics will continue to pose a public health challenge for years. This contract with the German government will ensure significant supply of vaccine doses to address potential public health threats by 2027,” said Sean Marett, Chief Business and Chief Commercial Officer at BioNTech. “We are proud to be in a position to be a long-term partner for Germany and remain steadfast in our commitment to continued investments in research and development aimed at bringing...

PEMBROKE, Bermuda, April 08, 2022 (GLOBE NEWSWIRE) — Sompo International, a leading global provider of commercial and consumer property and casualty (re)insurance, announced today the appointment of Kenneth Reilly as Executive Vice President, General Manager, Global Business Department, Sompo Holdings and Executive Vice President, Head of the new Sompo International Tokyo office, effective July 1, 2022. Ken will report to both Mikio Okumura, Chief Operating Officer, Sompo Holdings and James Shea, Chairman and CEO, Sompo International. James Shea shared, “Establishing our new Sompo International office in Tokyo is a big step forward towards increasing collaboration and education amongst the employees of Sompo International and the Sompo Insurance companies in Japan. I’m very excited to have Ken join to lead these efforts. Ken...

RESEARCH TRIANGLE PARK, N.C., April 08, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in some patients. During the investigation, the company will not enroll new patients in the REDEEM-1, REDEEM-2 or RENEW clinical trials. Patients currently enrolled in the trials are continuing on study drug at this time. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States, the European Union, Japan,...

DURHAM, N.C., April 08, 2022 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that TheraSkin coverage now includes three out of the four largest commercial plans in the U.S. along with Medicare and several regional commercial plans. Bioventus’ TheraSkin is a cellular and tissue-based treatment for difficult to heal chronic wounds and this expanded coverage adds more than 17 million medical lives to the existing coverage.   The results of Bioventus’ TheraSkin Randomized Controlled Trial (RCT) were published on January 26, 2022 in the International Wound Journal and demonstrated statistically significant improved wound healing when receiving the treatment versus standard of care. This recent publication further supplements the 13 previous...

— Anti-PD1-IL-2 BiSKIT (Bi-functional SuperKines for ImmunoTherapy) selectively stimulates anti-cancer immune cells via IL-2 agonism and prevents their exhaustion through PD-1 inhibition — Treatment with anti-PD-1-IL-2 BiSKIT led to statistically significant improvements in tumor growth inhibition and survival compared to the co-administration of its underlying components — Data highlight the versatility of the Superkine platform and the advantages of using a cis-binding approach to enhance the efficacy of checkpoint blockade TORONTO and HOUSTON, April 08, 2022 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced new preclinical data highlighting the potent anti-tumor efficacy of the next-generation...